Novartis to buy VC-backed Cadent Therapeutics

Novartis has agreed to acquire Cadent Therapeutics, a biopharmaceutical company, for a total potential consideration of $770 million.

17 December 2020•2 mins read

[data-article-body-skeleton]{display:none!important}

JavaScript is required to read this article. Please enable it in your browser and reload the page.

Healthcare M&A Deals Briefs